ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

Advisory Groups: Nominations Sought For Director’s Consumer Liaision Group

June 13, 1997

After 30 Years As NCI-Designated Center, Vermont Cancer Center Loses Core Grant.

November 14, 2008

Cancer Genome Atlas Researchers Link Cell Metabolism Pathways To Disease Aggressiveness

July 26, 2013

Commentary: NCI’s Budge Proposal ForFY2001 Offers A Blueprint for Research

November 26, 1999

Deals and Collaborations: Firms Get First Payment From Bristol-Myers for Taxol

March 5, 1999

Stop Cancer Changes Leaders, Focus, Sends $1.6M To NCI

August 30, 1991